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Abstract
Background: Gastrointestinal and respiratory diseases in calves and piglets lead to significant economic losses in
livestock husbandry. A high morbidity has been reported for diarrhea (calves ≤ 35 %; piglets ≤ 50 %) and for
respiratory diseases (calves ≤ 80 %; piglets ≤ 40 %). Despite a highly diverse etiology and pathophysiology of
these diseases, treatment with antimicrobials is often the first-line therapy. Multi-antimicrobial resistance in
pathogens results in international accordance to strengthen the research in novel treatment options. Medicinal plants
bear a potential as alternative or additional treatment. Based on the versatile effects of their plant specific
multi-component-compositions, medicinal plants can potentially act as ‘multi-target drugs’. Regarding the
plurality of medicinal plants, the aim of this systematic review was to identify potential medicinal plant
species for prevention and treatment of gastrointestinal and respiratory diseases and for modulation of the
immune system and inflammation in calves and piglets.
Results: Based on nine initial sources including standard textbooks and European ethnoveterinary studies, a
total of 223 medicinal plant species related to the treatment of gastrointestinal and respiratory diseases was
identified. A defined search strategy was established using the PRISMA statement to evaluate 30 medicinal
plant species starting from 20’000 peer-reviewed articles published in the last 20 years (1994–2014). This
strategy led to 418 references (257 in vitro, 84 in vivo and 77 clinical trials, thereof 48 clinical trials in
veterinary medicine) to evaluate effects of medicinal plants and their efficacy in detail. The findings indicate
that the most promising candidates for gastrointestinal diseases are Allium sativum L., Mentha x piperita L. and
Salvia officinalis L.; for diseases of the respiratory tract Echinacea purpurea (L.) MOENCH, Thymus vulgaris L. and
Althea officinalis L. were found most promising, and Echinacea purpurea (L.) MOENCH, Camellia sinensis (L.)
KUNTZE, Glycyrrhiza glabra L. and Origanum vulgare L. were identified as best candidates for modulation of
the immune system and inflammation.
Conclusions: Several medicinal plants bear a potential for novel treatment strategies for young livestock.
There is a need for further research focused on gastrointestinal and respiratory diseases in calves and piglets,
and the findings of this review provide a basis on plant selection for future studies.
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Background
A high standard of animal health and welfare is striven in
modern livestock husbandries. Health in early life repre-
sents a precondition for a superior constitution and re-
sults in a high productivity later in life. The mammalian
immune system is still immature in the first weeks of life
and, in combination with an inappropriate colostral sup-
ply, contact to pathogens often results in high morbidity
and mortality in young farm animals. Inadequate manage-
ment including long distance transports, fasting, commin-
gling of individuals from different sources, abrupt changes
in diet or incorrect diet, overcrowding of pens, improper
climate and suboptimal hygiene are crucially involved in
infectious diseases [1–6]. In calves and piglets, the first
contact sites for pathogens are the epithelia of the gastro-
intestinal and respiratory tract. Table 1 shows four of the
most important infectious disease complexes in calves and
piglets leading to a decreased animal performance and
welfare and therefore high economic losses.
In calves and piglets, a variety of pathogens can cause
gastrointestinal diseases. Neonatal calf diarrhea represents
the most frequent cause of calf losses [2, 7–9] with a mor-
tality of around 55 % in the U.S.A. and in Korea [10] and a
morbidity ranging from 12 % in the U.S.A., 23 % in
Canada up to 53 % in The Netherlands [1, 7, 11]. Insuffi-
cient colostral supply and failure of feeding or improper
diet are triggers for diarrhea in calves [12–14]. In suckling
and postweaning piglets an infection with enterotoxigenic
Escherichia coli strains has been reported to lead to high
economic losses as a result of a constant high morbidity
and mortality [15]. Verocytotoxin-producing Escherichia
coli infections can lead to more seldom but severe edema
disease in weaned pigs [16–18]. The prevalence of post-
weaning diarrhea has been reported to be 35 % in France
[19], the morbidity was stated to exceed 50 % in Finland
[20] and the mortality can be as high as 25 % without
therapy [17]. The incidence of neonatal diarrhea in piglets
depends on concentration of antibodies in sow’s colos-
trum. While piglets are protected by the antibodies in
sow’s milk, the predisposition for postweaning diarrhea in-
creases with weaning. Additional factors to the immuno-
logical gap, including abrupt changes in diet, an increase
in stomach pH, and changes in the enzymatic and cellular
configuration of the intestine lead to dysbiosis [6, 17, 21].
Respiratory diseases in calves and piglets have been
assessed as one of the most serious diseases with regard
to financial losses because of decreased weight gain,
costs for veterinary interventions and higher condemna-
tion at slaughter [22]. In fattening calves bovine respira-
tory disease is a considerable challenge with a morbidity
ranging from 49 % in Switzerland to 80 % in the U.S.A.
[23, 24]. There is a disposition of the bovine respiratory
tract to respiratory diseases. Improper microclimate,
noxious gases and distress through transportation are
predisposing factors additionally [25, 26]. Respiratory dis-
eases are also of high importance in pigs. The morbidity
rates differ between countries; a morbidity of 10 and 40 %
have been reported for Denmark and the U.S.A. respect-
ively [27, 28]. Mortality rates up to 15 % [29] have been re-
ported and attributed with the porcine respiratory disease
complex. The interaction of various pathogens as well as
housing conditions, management and genetic factors, were
reported to cause bronchopneumonia [27, 29].
Antibiotic therapy is often the first-line therapy of dis-
eases of the gastrointestinal and respiratory tract in calves
and piglets. A previously published study showed that fat-
tening calves receive antibiotics for 30 days on average.
Moreover, calves are frequently treated with reserve anti-
biotics such as fluorchinolones and cephalosporines of the
3. and 4. generation [30]. In pig production, routine pro-
and metaphylactic administration of antimicrobial agents
is a widely-used practice in herds suffering from neonatal
diarrhea, postweaning diarrhea or edema disease irre-
spective of increasing ineffectiveness in consequence of
bacterial resistance [6]. More than 60 % of the antibiotics
used in porcine husbandry are administered by oral group
treatment [31]. Data on antimicrobial resistance monitor-
ing indicated that 59 % of porcine Escherichia coli strains
from fecal samples showed resistance to at least one anti-
biotic and 12 % to more than four of the antibiotics that
were investigated [32]. With regard to increasing anti-
microbial resistance worldwide, the prevailing issue of re-
ducing antibiotics in food producing animals is seeking
for novel options to prevent and cure most common and
costly diseases. Improved biosecurity and housing condi-
tions, new feeding regimes, vaccinations and the use of
disease-resistant breeds are important provisions.
The diverse etiopathology and symptomatology of dis-
eases in young stock is a challenge and demands a multi-
targeted therapy. In contrast to chemically synthesized
mono-target drugs, multi-target drug characteristics are
typical for medicinal plants based on their multi-
component composition, which can lead to pleiotropic,
synergistic or additive effects in the organism [33, 34].
The broad spectrum of natural products from plants rep-
resents a prevailing and widely unemployed potential es-
pecially for medication of herbivore and omnivore
livestock [35]. Medicinal plants have been used worldwide
for prevention and treatment of diseases in human and
animals for centuries. Ethnoveterinary research and the
underlying documents describing traditional and recent
use of medicinal plants [36–38] could be exploited as al-
ternative or as supportive tools to reduce the use of antibi-
otics in livestock. Additionally, some medicinal plants are
known to modulate the immune system and inflammation
and could be used as a prophylaxis for infectious diseases.
Human clinical studies, experimental in vivo, ex vivo
and in vitro studies on medicinal plants are available,
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Table 1 Challenging infectious diseases in calves and piglets: pathogens, pathophysiology, resulting demands for prophylaxis and therapy
Disease complex Pathogens Pathophysiology/pathogenesis Demands for prophylaxis
and therapyBacteria Viruses Parasites
Calves
Neonatal Calf
Diarrhea1
Escherichia coli Bovine Coronavirus Cryptosporidium
parvum
secretory/malabsorptive/
maldigestive diarrhea
antimicrobial
Rotavirus dehydration antiviral
hypovolemic shock antidiarrheal
decrease in temperature antiadhesive
d-lactat acidosis astringent
septicaemia spasmolytic
neurological symptoms analgesic
apathy anti-inflammatory
recumbency orexigenic
reluctance to drink prebiotic
fever immunostimulant
Bovine Respiratory
Disease2
Mannheimia
haemolytica
Infectious bovine
rhinotracheitis virus
catharral/interstitial/fibrinous
bronchopneumonia
antimicrobial
Pasteurella
multocida
Parainfluenza type 3 virus fever antiviral
Histophilus somni Bovine respiratory
syncytial virus
increased respiratory rate analgesic
Mycoplasma bovis Bovine viral diarrhea virus dyspnoea anti-inflammatory
inappetence immunostimulant
nasal discharge mucolytic
coughing secretolytic
apathy antitussive
runting
Piglets
Neonatal Diarrhea Escherichia coli Rotavirus Cryptosporidium spp. secretory/malabsorbtive/
maldigestive diarrhea
antimicrobial
Postweaning
Diarrhea3
Clostridium
perfringens
Coronavirus Isospora suis enteritis antiviral
Lawsonia
intracellularis
Porcine Circovirus type 2 Trichuris suis colitis antidiarrheal
Brachyspira spp. Oesophagostomum
dentatum
dehydration antiadhesive
Salmonella spp. acidosis astringent
(Yersinia spp.) septicaemia spasmolytic
neurological symptoms analgesic
apathy anti-inflammatory
reduced growth rates orexigenic
prebiotic
immunostimulant
Porcine respiratory
disease complex4
Pasteurella
multocida
Porcine reproductive and
respiratory syndrome virus
suppurative/fibrinous/interstitial
bronchopneumonia
antimicrobial
Mycoplasma
hyopneumoniae
Swine influenza virus coughing antiviral
Porcine circovirus type 2 nasal discharge analgesic
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but there is a lack of comprehensive research for veter-
inary medicine, especially in young farm animals. There-
fore, the purpose of the underlying work is to gain
information about potential efficacy of medicinal plants
in human and veterinary medicine including in vitro, in
vivo and clinical studies.
The aim of this systematic literature review is to iden-
tify medicinal plant species or their extracts that are
promising candidates for use in diseases of the gastro-
intestinal and respiratory tract and for stimulation of the
immune system and prevention or therapy of inflamma-
tion in calves and piglets. Candidate plants should bear a
reliable potential for effective treatment and prevention
of these diseases. The information obtained can build a
basis for state-of-the-art experimental trials and clinical
studies with medicinal plants of interest for the treat-
ment of gastrointestinal and respiratory diseases and for
the modulation of the immune system and inflammatory
processes in calves and piglets.
Methods
The design of the systematic review was ‘a priori’ indi-
vidually developed according to the recommendations of
the PRISMA statement [39, 40] and AMSTAR measure-
ment tool [41]. The research question was designed fol-
lowing the PICOS scheme [39]: the population are
calves and piglets in livestock farming, the intervention
is a treatment with medicinal plants, the comparator is
no treatment, a placebo or standard treatment, the out-
come is the effect of the plant, the study design included
in vitro, ex vivo, in vivo and clinical trials. The detailed
protocol of the systematic review is provided in the
Additional file 1.
Selection of plant species
To choose eligible plant species, different initial sources
were screened in respect to plant species frequently rec-
ommended for the treatment of gastrointestinal diseases,
particularly unspecified or infectious diarrhea and
gastrointestinal spasms (QA) and respiratory diseases
(QR) as well as those plants that have been reported to
modulate the immune system and affect inflammation in
infectious diseases (QL). Regarding the intended use of
medicinal plants in Western livestock husbandry, poten-
tial plant species should be economically available or
easy to cultivate in Europe. The initial sources included
standard literature, based on traditional empiric know-
ledge and historical literature of veterinary [42–45], and
human phytotherapy [46], peer-reviewed publications of
European [47] and in particular Swiss ethnoveterinary
medicine [36, 38] and a report of the European Food
Safety Authority (EFSA) [48] focusing on the use of plants
as feed additives in animal production. All plant species
of these sources connected to one or more of the indica-
tions were recorded including the used part(s) of plant, the
route of administration, the dosage, the contraindications
and adverse effects (Additional file 1). Based on the plant
species that had been mentioned in at least three different
initial sources for the same indication, a preliminary selec-
tion was established. This selection was sent to three spe-
cialists in European veterinary phytotherapy to capitalize
their experience. The experts were asked to comment on
the preliminary selection of plant species regarding the
most common ones being particularly suitable for treatment
and prevention of gastrointestinal and respiratory diseases.
Selection of scientific references
Bibliographic search
The chosen plant species were included in the following
step. A bibliographic web-based search was conducted
based on the recommendations of the PRISMA statement
[39, 40] and AMSTAR measurement tool [41]. An intro-
duction in scientific bibliographic literature searches and
continuous support was provided by a professional librar-
ian. The bibliographic sources used included PubMed [49]
and Web of Science [50]. Both were consulted in the time
between 2015-02-16 and 2015-02-19 by one person. The
search terms consisted of the Latin name, the common
trivial name in English and the pharmaceutical denomin-
ation in Latin (e.g. “Foeniculum vulgare” OR “fennel” OR
“foeniculi fructus”). In the PubMed keyword search, the
results were refined with the subjects ‘complementary
Table 1 Challenging infectious diseases in calves and piglets: pathogens, pathophysiology, resulting demands for prophylaxis and therapy
(Continued)
Actinobacillus
pleuropneumoniae
(Streptococcus
suis)
increased respiratory rate anti-inflammatory
(Haemophilus
parasuis)
fever immunostimulant
reduced growth rates mucolytic
runting secretolytic
antitussive
1[10–13] 2[3–5, 23, 25] 3[6, 15–18] 4[22, 27, 29]
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medicine’, ‘dietary supplements’, ‘systematic review’, ‘toxicol-
ogy’ and ‘veterinary science’. In the PubMed search with
MeshTerms, only the Latin name of the plant was used
and the subheadings ‘adverse effects’, ‘analysis’, ‘drug effects’,
‘microbiology’, ‘pharmacology’, ‘therapeutic use’, ‘therapy’
and ‘toxicity’. In the Web of Science database, the search
was conducted in the research domain ‘science technol-
ogy’ and the results were refined with the research areas
‘pharmacology’, ‘infectious diseases’, ‘toxicology’, ‘veterinary
sciences’, ‘microbiology’, ‘gastroenterology’, ‘integrative com-
plementary medicine’, ‘general internal medicine’, ‘respira-
tory system’ and ‘virology’. Overall, only peer-reviewed
articles written in English or German language and pub-
lished between 1994 and 2014 were considered for further
evaluation to ensure contemporary scientific quality and
timeliness of the review. The references found were saved
in an EndNote X7 data base [51] and the information on
each plant was stored in a separate folder in this database.
Duplicates were removed for each plant species.
In some studies more than one plant species was in-
vestigated (e. g. a screening of plant species against E.
coli [52]). In other studies, more than one indication was
considered and investigated (e. g. spasmolytic effect of
Plantago lanceolata L. on intestine and trachea [53]).
Therefore, the following definition of “reference” was
introduced:
reference = indication per plant species per peer-
reviewed publication
Term-list search
A term-list search was conducted within each plant spe-
cies using the search function in EndNote X7 [51]. Only
references containing one of the following predefined key-
words occurring in the title or the abstract were included:
‘pig*’, ‘calv*’, ‘muco*’, ‘spasmo*’, ‘anti*’ (e.g. antimicrobial, anti-
bacterial, antiviral, antifungal, antioxidant, antinocicep-
tive…), ‘wean*’, ‘intest*’, ‘gastro*’, ‘pulmo*’, ‘broncho*’,
‘pharma*’, ‘eff*’(e.g. efficiency, effectivity, effect), ‘bioactiv*’,
‘constitu*’. References containing the terms ‘tumor’ or
‘cancer’ were excluded. The check of the excluded refer-
ences lowered the risk to exclude relevant references.
Refining with inclusion and exclusion criteria
The remaining references were refined using a selective
screening of the title. References remained if the content
suffices the objective of the review. Therefore, inclusion cri-
teria were pre-defined by two scientists and lead to an in-
clusion of all references containing investigations of plants
in in vitro, ex vivo, in vivo or clinical studies. Besides these
categories, the evaluation included the following inclusion
criteria: antibacterial effect, enhancement of antibiotics,
antiviral effect, antiprotozoal effect, anti-inflammatory ef-
fect, analgesic effect, spasmolytic effect, antiadhesive effect,
astringent effect, secretolytic or mucolytic effect, antitussive
effect, and other effects on the gastrointestinal tract, re-
spiratory tract or immune system, treatment of diarrhea,
bacterial or viral infections of the gastrointestinal tract or
respiratory tract, bronchopneumonia, common cold, cough
as well as ingredients, constituents, components of plants
and the detection or extraction of them, toxic activity or ad-
verse effects due to a treatment with plants.
Exclusion criteria were chosen in order to exclude refer-
ences dealing with other plant species or subspecies than
those we focused on, a mixture of different plant species
investigated as one single preparation, pathogens affecting
only humans, diseases regulated by laws, cultivation or
breeding of plants, plant genetics, seeds and fertilizers, re-
gional reservoirs, habitats or demands for growing of
plants, plant pathology, plant protection systems or pesti-
cides, ecology, geology, ethology, sociology, the usage of
the plant as food, food technology or food-packaging, the
use of the plant as a repellent or insecticide, other medical
branches, other diseases or apparatuses than mentioned in
the inclusion criteria (e.g. dermatology, cardiology, oncol-
ogy, nephrology, diabetes) as well as other animal classes
than mammalians and birds.
Classification
Thereby the references were classified into different cat-
egories of trial types. Studies investigating diseases oc-
curring naturally in the investigated animal species or in
humans were categorized as ‘clinical references’. Trials
investigating diseases or the effect of plants in animal
models were categorized as ‘in vivo references’. Studies
using pathogens, cell layers or ex vivo models were cate-
gorized as ‘in vitro references’. Studies investigating the
pharmacologic characteristics, constituents or the detec-
tion of them were categorized as ‘pharmacognostic refer-
ences’ and the evaluation of plants summarizing other
studies as ‘review references’.
In the last step, abstracts of the remaining clinical, in
vivo and in vitro references were studied by one person.
During this process, further references were excluded be-
cause they did not match the predefined selection criteria.
Assessment of clinical, in vivo and in vitro references
The remaining references were assessed by the following
characteristics: used plant species, type of reference
(clinical, in vivo or in vitro), indication of the reference
inspired by the ATCvet classification (QA, QR, QL) [54],
animal species used, study design, pharmaceutical form
of the plant, type of application, concentration tested,
dosage or minimal inhibition concentration and, if avail-
able, the tested pathogen.
To assess the potential of the selected plant species, a
reconciliation of the demands for prophylaxis and ther-
apy of gastrointestinal and respiratory diseases with the
Ayrle et al. BMC Veterinary Research  (2016) 12:89 Page 5 of 31
hypothesized and tested effects of the plants was per-
formed. The demands for prophylaxis and therapy were de-
rived from the pathophysiology of the focused diseases
(Table 1). According to these data, plant-derived treat-
ment options should act bacteriostatic or bactericidal, syn-
ergistically with antibiotics, antiviral, antiprotozoal, anti-
inflammatory, analgesic, immunomodulatory, antidiarrheal,
antiadhesive, spasmolytic, astringent, expectorant or anti-
tussive (depending on the indication). The conclusion of a
trial on the investigated hypothesized effect of the plant
species (Additional file 3) was transferred in the following
assessment. To compare the potential of the plant species,
a scoring system was established. For each significantly
proven effect, the plant species one point was given, while
for each uncertain effect, zero points were assigned, and for
each disproved effect a point was subtracted (for more de-
tails see Additional file 1). Clinical studies were given more
weight compared to in vivo studies followed by in vitro
studies. Clinical studies were given a weight of three, in vivo
studies two, and in vitro studies one. The weighted average
of the sum of points of the clinical, in vivo, and in vitro
scores served as the final score. The scores were used to
identify the plant species that are the most efficacious op-
tions for related disease complexes.
Score ¼ 3 x ðnumber of proven effects in clinical studies –
number disproof of effects in clinical studiesÞ þ
2 x ðnumber of proven effects in in vivo studies ‐
number ofdisproof of effects in in vivo studiesÞ þ
1 x ðnumber of proven effects in in vitro studies‐
number of disproof of effects of in vitro studiesÞ
Results
The procedure of this systematic literature review is vi-
sualized in Fig. 1. The screening of ethnoveterinary re-
search and standard phytotherapeutic textbooks (initial
sources) led to a total of 223 plant species recommended
for the treatment and prophylaxis of gastrointestinal
(diarrhea and intestinal spasms) and respiratory diseases
in human and animals. A number of 134 different plant
species were recommended for QA, 121 for QR and 44
for QL (Additional file 2). A preliminary selection of 29
plant species, recommended in at least three different
sources for the same indication, was established. There-
from, 17 plant species were recommended for QA, 15
for QR and 8 for QL. The specialists review led to an
addition of one plant species (Origanum vulgare L.) to
the preliminary list including finally 30 plant species. All
of these plant species meet the claims for cost-efficiency
or cultivability in Europe.
In the subsequent bibliographic search 20,364 refer-
ences (after removal of duplicates) were found for the 30
plants species (Table 2). During the term-list search, the
amount of relevant references led to a reduction of refer-
ences with 6,800 remaining references. An ensuing
random check of the excluded references confirmed the
selected terms. The subsequent screening of titles led to
a number of 2,797 eligible references, which were classi-
fied into the categories ‘clinical references’ (243), ‘in vivo
references’ (428), ‘in vitro references’ (1258), ‘pharmacog-
nostic references’ (704) and ‘review references’ (164).
The terminal screening of the abstracts of all clinical, in
vivo and in vitro references revealed a final number of
418 references (77 clinical, 84 in vivo, 258 in vitro)
(Additional file 3). Due to the fact that more than one
reference could be defined from some studies, the system-
atic literature research led to a number of 378 studies
representing the effects and efficacy of 29 plant species in
418 references. For one plant species, Quercus robur L.,
no references were found according to the criteria.
A total of 19,077 references were excluded because they
did not match the predefined selection criteria. Predomin-
ant reasons for exclusion included that the content of title
and abstract did not correspond to the focus of the review
(e. g. pathogens were not the pathogens of the focused dis-
eases). Other reasons were missing abstracts (in 212 refer-
ences) or publications that were not peer-reviewed.
From the 418 remaining references, 48 references based
on clinical studies were veterinary origin with 19 swine
studies, 5 cattle studies, 17 horse studies, and 4 studies in
rabbits. A number of 370 references include studies in
humans (29 clinical, 84 in vivo and 257 in vitro studies). A
number of 77 in vivo references used laboratory rodents
(rats, mice, guinea-pigs) and three studies used cats as an
animal model. For gastrointestinal indications (QA), 198
references were found, 57 references were related to re-
spiratory diseases (QR), and 163 references aimed at the
modulation of the immune system and inflammation pro-
cesses (QL). Most references coping with the inclusion cri-
teria were found for Echinacea purpurea L. MOENCH.
(48 references), Origanum vulgare L. (36 references) Thy-
mus vulgaris L. (36 references), Camellia sinensis (L.)
KUNTZE (32 references), and Allium sativum L. (31 refer-
ences). The required effects of a treatment and the proven
effects of the plant species as mono-substances for each
indication are shown in Tables 3, 4 and 5. In Table 6, the
most promising plant species of the peer-reviewed refer-
ences according to the scoring system for each indica-
tion (QA, QR and QL), as well as the most frequently
recommended plant species of the traditional references
(Additional file 2) are shown. According to the scoring
system, the two most promising plant species are
Echinacea purpurea (L.) MOENCH (for QR and QL)
and Allium sativum L. (for QA).
Discussion
There is a large amount of evidence-based knowledge
about medicinal plants, represented by 20,364 studies fo-
cusing on 30 medicinal plant species from the last
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20 years considering peer-reviewed publications in English
or German language. The emergence of multi-drug resist-
ance in human and animal pathogens results in inter-
national accordance to strengthen the research in novel
treatment options. Medicinal plants and their extracts
might be an option to prevent and cure livestock diseases.
Evaluation of the search strategy
This systematic review was designed and performed ac-
cording to the guidelines of the PRISMA statement and
AMSTAR measurement tool [39–41]. Due to the fact that
we searched for available data on a largely underrepre-
sented topic in the last decades, only a small number of
Fig. 1 Process of the systematic literature review
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veterinary clinical data is currently available. Therefore,
the search strategy was adapted to gain as much plant spe-
cific information as possible and to cope with the complex
research question. Human clinical studies, experimental
in vivo studies with laboratory animals as well as ex vivo
and in vitro studies were included as well. To avoid the
Table 2 Quantifying and categorizing of scientific publications regarding 30 medicinal plants during bibliographic literature research
process
Plant species Common
name
All references
imported from
WoS1 and PM2
after removal
of duplicates
After keyword
search in titles
and abstracts
with endnote
Pharmacognostic
studies
Reviews After checking
of relevance,
regarded for
the assessment
of plant species
Clinical
studies
In vivo
studies
In vitro and
ex vivo
studies
Achillea millefolium L. yarrow 345 157 14 2 15 2 3 10
Agrimonia eupatoria L. agrimony 73 37 10 0 2 1 0 1
Allium sativum L. garlic 1149 630 24 14 31 9 5 17
Althaea officinalis L. marshmellow 62 29 6 1 6 0 4 2
Camellia sinensis (L).
KUNTZE
green tea 2052 804 53 21 32 4 6 22
Carum carvi L. caraway 191 95 28 6 5 0 1 4
Cetraria islandica (L.)
ACH.
Icelandic
moss
118 46 8 0 4 1 1 2
Echinacea purpurea (L.)
MOENCH
purple
coneflower
869 364 45 18 48 14 8 26
Foeniculum vulgare (L.)
MILL.
fennel 825 308 46 6 18 1 4 13
Glycyrrhiza glabra L. liquorice 597 252 43 8 26 3 7 16
Linum usitatissimum L. linseed 762 227 12 5 7 3 3 1
Malva sylvestris L. wild mallow 243 50 2 2 4 0 3 1
Matricaria recutita L. camomile 908 305 43 7 22 1 7 14
Mentha x piperita L. peppermint 1331 425 35 23 21 8 0 13
Origanum vulgare L. oregano 904 526 42 0 36 10 4 22
Picea abies (L.) H.KARST. norway
spruce
1031 153 0 0 1 0 0 1
Pimpinella anisum L. anis 453 147 12 2 12 2 0 10
Plantago lanceolata L. english
plantain
532 136 7 2 6 1 0 5
Potentilla erecta (L.)
RAEUSCH.
tormentil 49 15 3 2 3 2 0 1
Primula veris L. cowslip 106 23 2 0 1 0 0 1
Quercus robur L. english oak 1210 165 7 0 0 0 0 0
Rubus fruticosus L. blackberry 583 172 34 0 6 0 1 5
Rumex ssp. L. dock 939 208 15 2 11 0 4 7
Salix ssp. L. willow 915 171 20 13 6 0 1 5
Salvia officinalis L. sage 902 372 67 5 20 7 7 6
Sambucus nigra L. elderberry 891 169 19 4 7 1 2 4
Thymus vulgaris L. thyme 831 372 52 3 36 6 2 28
Tussilago farfara L. coltsfoot 101 36 14 0 4 0 1 3
Urtica dioica L. stinging
nettle
760 251 16 10 20 1 6 13
Vaccinium myrtillus L. blueberry 632 155 25 7 8 0 4 4
suma 20364 6800 704 164 418 77 84 257
adue to the definition of reference (trial x plant species x indication) the sum may contain some trials more than one time; 1WoS =Web of Science [50];
2PM = PubMed [49]
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Table 3 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming gastrointestinal indicationsc
Plant species Number of
references
Type of
reference
Antibacterial Synergism
with AB
Antiviral Anti
protozoal
Anti
adhesive
Anti
diarrheal
Spasmolytic Immuno
stimulant
Antiin
flammatory
Analgesic Hypothesis
proved
+ ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o
Achillea millefolium L. 6 in vitro 21 42
2 in vivo +
clinical
13 14
Allium sativum L. 12 in vitro 125 16
9 in vivo +
clinical
27 18 29 210 111 112 213
Althaea officinalis L. 2 in vitro 214
0 in vivo +
clinical
Camellia sinensis (L.)
KUNTZE
8 in vitro 615 116 117 118
3 in vivo +
clinical
219 220
Carum carvi L. 4 in vitro 321 122
1 in vivo +
clinical
123
Echinacea purpurea
(L.) MOENCH
0 In vitro
1 in vivo +
clinical
124
Foeniculum vulgare
(L.) MILL.
10 in vitro 625 126 127 128 129 130
2 in vivo +
clinical
131 132
Glycyrrhiza glabra L. 9 in vitro 433 234 135 136 137
4 in vivo +
clinical
238 139 140
Linum usitatissimum L. 0 in vitro
3 in vivo +
clinical
141 142 143 144
Matricaria recutita L. 9 in vitro 545 446
3 in vivo +
clinical
247 148
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Table 3 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming gastrointestinal indicationsc (Continued)
Plant species Number of
references
Type of
reference
Antibacterial Synergism
with AB
Antiviral Anti
protozoal
Anti
adhesive
Anti
diarrheal
Spasmolytic Immuno
stimulant
Antiin
flammatory
Analgesic Hypothesis
proved
+ ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o
Mentha x piperita L. 13 in vitro 849 150 151 352
7 in vivo +
clinical
153 154 455 156
Origanum vulgare L. 21 in vitro 1857 258 159
8 in vivo +
clinical
160 261 162 163 264 165 166
Picea abies (L.)
H.KARST.
1 in vitro 167
0 in vivo +
clinical
Pimpinella anisum L. 7 in vitro 368 269 270 171
0 in vivo +
clinical
Plantago lanceolata L. 1 in vitro 172
1 in vivo +
clinical
173
Potentilla erecta (L.)
RAEUSCH.
0 in vitro
2 in vivo +
clinical
174 175
Rubus fruticosus L. 1 in vitro 176
0 in vivo +
clinical
Rumex ssp. L. 4 in vitro 477
1 in vivo +
clinical
178
Salix ssp. L. 1 in vitro 179
0 in vivo +
clinical
Salvia officinalis L. 6 in vitro 580 181
5 in vivo +
clinical
382 283 1
84
185 186 187
Sambucus nigra L. 1 in vitro 188
1 in vivo +
clinical
189
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Table 3 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming gastrointestinal indicationsc (Continued)
Thymus vulgaris L. 14 in vitro 1090 191 392
3 in vivo +
clinical
293 194
Plant species Number of
references
Type of
reference
Antibacterial Synergism
with AB
Antiviral Anti
protozoal
Anti
adhesive
Anti
diarrheal
Spasmolytic Immuno
stimulant
Antiin
flammatory
Analgesic Hypothesis
proved
+ ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o
Tussilago farfara L. 1 in vitro 195
0 in vivo +
clinical
Urtica dioica L. 6 in vitro 296 297 298
2 in vivo +
clinical
299
Vaccinium myrtillus L. 2 in vitro 1100 1101
2 in vivo +
clinical
1102 1103 1104
Sum of plant species
for each effect
in vitro 18 6 3 6 0 0 2 0 0 2 0 1 0 0 1 0 0 0 10 0 0 0 0 0 3 0 0 0 0 0 0 0 0
in vivo +
clinical
6 2 3 0 0 0 0 0 0 3 0 0 1 0 0 7 2 1 6 0 0 3 0 2 6 1 1 0 0 0 6 0 2
Sum of assessments in vitro 93 8 5 7 0 0 3 0 0 2 0 0 0 0 1 0 0 0 20 0 0 0 0 0 3 0 0 0 0 0 0 0 0
in vivo +
clinical
11 2 4 0 0 0 0 0 0 6 0 0 1 0 0 10 2 1 7 0 0 3 0 3 7 1 1 0 0 0 7 0 2
aAssessment = conclusion of a reference on a hypothesized effect; breference = trial x plant species x indication; cparticularly unspecified or infectious diarrhea and gastrointestinal spasms + = reference proves evidently
the hypothesized effect; ? = reference shows uncertain hypothesized effect; o = reference does not prove evidently the hypothesized effect
1[147, 148] 2[149–152] 3[153] 4[154] 5[69–76, 155–158] 6[69] 7[63, 66] 8[159] 9[62, 160] 10[63, 64] 11[66] 12[77] 13[161, 162] 14[163, 164] 15[165–170] 16[170] 17[171] 18[172] 19[124, 125] 20[124, 173] 21[174–176] 22[177]
23[178] 24[179] 25[175, 176, 180–183] 26[184] 27[185] 28[181] 29[186] 30[187] 31[188] 32[189] 33[143, 190–192] 34[142, 193] 35[145] 36[194] 37[195] 38[196, 197] 39[141] 40[198] 41[199] 42[199] 43[200] 44[201] 45[202] [175, 185,
203, 204] 46[205–208] 47[209, 210] 48[189] 49[176, 211–216] 50[217] 51[214] 52[88, 205, 218] 53[219] 54[220] 55[86, 87, 221, 222] 56[223] 57[52, 118, 175, 224–237] 58[238, 239] 59[240] 60[241] 61[242, 243] 62[244] 63[245]
64[244, 246] 65[247] 66[248] 67[249] 68[175, 250, 251] 69[252, 253] 70[251, 254] 71[255] 72[53] 73[256] 74[257] 75[258] 76[259] 77[180, 260–262] 78[263] 79[264] 80[175, 211, 233, 237, 265] 81[252] 82[266–268] 83[267, 268]
84[269] 85[270] 86[269] 87[268] 88[271] 89[272] 90[52, 118–120, 175, 176, 226, 250, 252, 273] 91[274] 92[113, 275, 276] 93[277, 278] 94[279] 95[280] 96[191, 281] 97[185, 282] 98[145] 99[283, 284] 100[285] 101[259] 102[286]
103[287] 104[286]
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Table 4 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming respiratory indications
Plant species Number of
references
Type of
reference
Anti-bacterial Synergism
with AB
Antiviral Spasmolytic Expectorant Antitussive Immuno-stimulant Anti-inflammatory Analgesic Hypothesis
proved
+ ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o + ? o
Achillea millefolium L. 2 in vitro 21
1 in vivo + clinical 12
Agrimonia eupatoria L. 1 in vitro 13
0 in vivo + clinical
Allium sativum L. 1 in vitro 14
0 in vivo + clinical
Althaea officinalis L. 0 in vitro
4 in vivo + clinical 45
Camellia sinensis (L).
KUNTZE
0 in vitro
2 in vivo + clinical 16 17 18
Cetraria islandica (L.)
ACH.
0 in vitro
1 in vivo + clinical 19
Echinacea purpurea (L.)
MOENCH
3 in vitro 210 211
8 in vivo + clinical 112 113 114 215 116 217 218
Foeniculum vulgare (L.)
MILL.
2 in vitro 219
0 in vivo + clinical
Glycyrrhiza glabra L. 1 in vitro 120
2 in vivo + clinical 121 122
Mentha x piperita L. 1 in vitro 123
0 in vivo + clinical
Pimpinella anisum L. 2 in vitro 224
0 in vivo + clinical
Plantago lanceolata L. 1 in vitro 125
0 in vivo + clinical
Primula veris L. 1 in vitro 126
0 in vivo + clinical
Rubus fruticosus L. 0 in vitro
1 in vivo + clinical 127
Rumex ssp. L. 2 in vitro 128 229
0 in vivo + clinical
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Table 4 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming respiratory indications (Continued)
Salvia officinalis L. 0 in vitro
2 in vivo + clinical 130 131
Sambucus nigra L. 1 in vitro 132
1 in vivo + clinical 133
Thymus vulgaris L. 9 in vitro 334 635
1 in vivo + clinical 136
Tussilago farfara L. 1 in vitro 137
1 in vivo + clinical 138 139
Urtica dioica L. 3 in vitro 340
1 in vivo + clinical 141
Vaccinium myrtillus L. 1 in vitro 142
0 in vivo + clinical
Sum of plant species
for each effect
in vitro 5 0 0 0 0 0 6 0 0 7 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0
in vivo + clinical 2 0 0 0 0 1 2 0 1 2 0 0 2 0 0 4 0 0 1 0 0 2 0 0 1 0 0 3 0 1
Sum of assessments in vitro 9 0 0 0 0 0 8 0 0 15 0 0 0 0 0 0 0 0 0 0 1 2 0 0 0 0 0 0 0 0
in vivo + clinical 2 0 0 0 0 1 2 0 1 2 0 0 2 0 0 7 0 0 2 0 0 2 0 0 1 0 0 4 0 2
a Assessment = conclusion of a reference on a hypothesized effect; b reference = trial x plant species x indication; + = reference proves evidently the hypothesized effect; ? = reference shows uncertain hypothesized
effect; o = reference does not prove evidently the hypothesized effect
1 [288, 289] 2 [290] 3 [291] 4 [292] 5 [293–296] 6 [297] 7 [298] 8 [297] 9 [299] 10 [300, 301] 11 [103, 301] 12 [302] 13 [94] 14 [96] 15 [302, 303] 16 [96] 17 [95, 304] 18 [305, 306] 19 [307, 308] 20 [309] 21 [140] 22 [139] 23 [89] 24
[310, 311] 25 [53] 26 [312] 27 [313] 28 [314] 29 [315] 30 [293] 31 [316] 32 [300] 33 [317] 34 [191, 318, 319] 35 [113–116, 320, 321] 36 [108] 37 [322] 38 [323] 39 [323] 40 [322, 324, 325] 41 [326] 42 [327]
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Table 5 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming the modulation of the
immune system and inflammation
Plant species Number of references Type of reference Immunostimulant Antiinflammatory Analgesic Hypothesis proved
+ ? o + ? o + ? o + ? o
Achillea millefolium L. 2 in vitro 21
2 in vivo + clinical 12 13 14
Agrimonia eupatoria L. 0 in vitro
1 in vivo + clinical 15
Allium sativum L. 4 in vitro 16 17 28
5 in vivo + clinical 59 110
Camellia sinensis (L). KUNTZE 14 in vitro 311 1212
5 in vivo + clinical 213 214 115
Cetraria islandica (L.) ACH. 2 in vitro 216
1 in vivo + clinical 117
Echinacea purpurea (L.) MOENCH 23 in vitro 1618 119 620
13 in vivo + clinical 921 222 123 124
Foeniculum vulgare (L.) MILL. 1 in vitro 125
3 in vivo + clinical 126 327
Glycyrrhiza glabra L. 6 in vitro 428 229
4 in vivo + clinical 330 131 132
Linum usita-tissimum L. 1 in vitro 133
3 in vivo + clinical 134 235 136
Malva sylvestris L. 1 in vitro 137
3 in vivo + clinical 138 239 140
Matricaria recutita L. 5 in vitro 141 442
5 in vivo + clinical 143 144 245 246
Mentha x piperita L. 0 in vitro
1 in vivo + clinical 147
Origanum vulgare L. 1 in vitro 148
6 in vivo + clinical 249 350 151
Pimpinella anisum L. 1 in vitro 152
2 in vivo + clinical 153 154
Plantago lanceolata L. 3 in vitro 355
0 in vivo + clinical
Potentilla erecta (L.) RAEUSCH. 1 in vitro 156
0 in vivo + clinical
Rubus fruticosus L. 4 in vitro 457
0 in vivo + clinical
Rumex ssp. L. 1 in vitro 158
3 in vivo + clinical 259 260
Salix ssp. L. 4 in vitro 461
1 in vivo + clinical 162
Salvia officinalis L. 0 in vitro
7 in vivo + clinical 163 164 165 466 267
Sambucus nigra L. 2 in vitro 168 169
1 in vivo + clinical 170
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risk of source selection bias, multiple types of sources
were used initially: standard textbooks, peer-reviewed
publications, a governmental report, and personal com-
munications with experts. The risk of introducing data-
base bias was reduced by using two different and
independent databases and by using the Mesh Terms
function of PubMed. The selection of the 30 traditionally
used plant species may bear a sampling bias. European
ethnoveterinary and traditional administrations of medi-
cinal plants were screened to identify promising plant spe-
cies for the bibliographic search. Due to our strategy, it is
likely that frequently studied plant species come up as
more promising compared to less frequently studied
plants. Additionally, the timeliness of the review excluded
studies published before 1994 which may be accepted in
science for decades by e.g. the European Scientific Co-
operative on Phytotherapy [55]. As a consequence, plants
including Malva sylvestris L., Potentilla erecta (L.)
RAEUSCH, Primula veris L., Quercus robur L. or Picea
abies (L.) H.KARST. appeared less promising, although
they are an integral element of traditional medicine.
Comparison of traditional phytotherapy with up-to-date
knowledge
The most promising plant species of the peer-reviewed
publications of the last 20 years were compared to the
most common traditional administrations of the initial
sources (Table 6). For the most promising plant species
62, 30 and 27 % are also frequently recommended in the
initial sources for QA, QR and QL, respectively. The re-
sults confirmed the rationale of some traditional
administrations of medicinal plants. Cases where the
traditional applications were not confirmed by current
studies, may be explained by the fact that only studies
published between 1994 and 2014 were considered.
Nevertheless, for many of these plant species broad sci-
entific substantiation exists. For example, ESCOP mono-
graphs are available for Linum usitatissimum L.,
Pimpinella anisum L., Cetraria islandica (L.) ACH.,
Primula veris L. and Salix ssp..
Complexity of varying chemistry
It is important to consider that the amount of active con-
stituents in plants depends on environmental factors.
Based on the plant cultivars used climatic and geographic
conditions, quality of the soil and method of cultivation
and harvest influence the phytochemical composition of
the plant and therefore, different amounts of constituents
can be found in different batches. The used part of plant,
widely divergent post-harvesting processing and methods
of extraction and stabilization affect the chemistry of phy-
topharmaceuticals [56]. Environmental factors and post
harvesting procedures are likely to explain varying ef-
fectiveness of a medicinal plant in different studies as
reported for Echinacea [57, 58]. Therefore, a direct
comparison of the outcome of the studies is difficult
especially because of the lack of information regard-
ing the phytochemical composition of the used test
material. The use of pharmacopoeia quality in future
research would ensure a defined amount of active
constituents [59].
Table 5 Assessmenta of medicinal plants based on peer-reviewed referencesb of the last 20 years aiming the modulation of the
immune system and inflammation (Continued)
Thymus vulgaris L. 5 in vitro 571
4 in vivo + clinical 172 173 274
Tussilago farfara L. 1 in vitro 175
0 in vivo + clinical
Urtica dioica L. 4 In vitro 276 277
4 in vivo + clinical 378 179 180
Vaccinium myrtillus L. 1 In vitro 181
2 in vivo + clinical 182 283
Sum of plant species for each effect in vitro 6 3 0 20 0 0 0 0 0 0 0 0
in vivo + clinical 9 4 6 13 0 1 12 0 1 1 1 1
Sum of assessments in vitro 29 3 0 56 0 0 0 0 0 0 0 0
in vivo + clinical 24 4 7 20 0 1 20 0 1 1 1 1
aAssessment = conclusion of a reference on a hypothesized effect; breference = trial x plant species x indication; + = reference proves evidently the hypothesized
effect; ? = reference shows uncertain hypothesized effect; o = reference does not prove evidently the hypothesized effect
1[328, 329] 2[330] 3[331] 4[331] 5[332] 6[333] 7[334] 8[78, 80] 9[65, 67, 68, 79, 335] 10[79] 11[133, 336, 337] 12[336, 338–348] 13[134, 349] 14[131, 350] 15[351] 16[352,
353] 17[354] 18[99, 100, 355–368] 19[369] 20[102, 370–374] 21[93, 97, 98, 375–380] 22[381, 382] 23[383] 24[384] 25[385] 26[386] 27[386–388] 28[144, 334, 389, 390]
29[391, 392] 30[138, 380, 393] 31[394] 32[394] 33[395] 34[396] 35[397, 398] 36[397] 37[399] 38[400] 39[401, 402] 40[401] 41[403] 42[404–407] 43[408] 44[409] 45[410, 411]
46[410, 412] 47[413] 48[414] 49[415, 416] 50[417–419] 51[420] 52[421] 53[422] 54[423] 55[392, 424, 425] 56[426] 57[427–430] 58[431] 59[432, 433] 60[432, 434] 61[426, 435–
437] 62[438] 63[439] 64[440] 65[441] 66[442–445] 67[442, 443] 68[446] 69[430] 70[447] 71[436, 448–450] 72[451] 73[451] 74[417, 452] 75[453] 76[454, 455] 77[456, 457]
78[138, 458, 459] 79[460] 80[460] 81[344] 82[461] 83[461, 462]
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Table 6 Promising medicinal plants for treatment and prophylaxis of gastrointestinal and respiratory diseases and for modulation of
the immune system and inflammation
Indication Traditional applications in initial sources1 (number
of references recommending the plant for the indication)a
Peer-reviewed references
(sum of points gathered in the scoring system2)b
Gastrointestinal tract Matricaria recutita L. (7) Allium sativum L. (41)
Foeniculum vulgare (L.) MILL. (6) Mentha x piperita L. (30)
Potentilla erecta (L.) RAEUSCH (5) Salvia officinalis L. (27)
Linum usitatissimum L. (5) Origanum vulgare L. (24)
Rubus fruticosus L. (5) Camellia sinensis (L.) KUNTZE (18)
Thymus vulgaris L. (4) Matricaria recutita L. (15)
Quercus robur L. (4) Glycyrrhiza glabra L. (14)
Mentha x piperita L. (4) Thymus vulgaris L. (13)
Urtica dioica L. (4) Foeniculum vulgare (L.) MILL. (7)
Vaccinium myrtillus L. (4) Carum carvi L. (6)
Salvia officinalis L. (4) Pimpinella anisum L. (6)
Carum carvi L. (4) Rumex sp. L. (6)
Camellia sinensis (L.) KUNTZE (4) Urtica dioica L. (6)
Achillea millefolium L. (4)
Respiratory tract Thymus vulgaris L. (7) Echinacea purpurea (L.) MOENCH (10)
Pimpinella anisum L. (6) Thymus vulgaris L. (10)
Althaea officinalis L. (5) Althaea officinalis L. (8)
Cetraria islandica (L.) ACH. (5) Glycyrrhiza glabra L. (5)
Primula veris L. (5) Salvia officinalis L. (5)
Foeniculum vulgare (L.) MILL. (4) Tussilago farfara L. (5)
Sambucus nigra L. (4) Urtica dioica L. (5)
Malva sylvestris L. (4) Achillea millefolium L. (4)
Allium sativum L. (4) Camellia sinensis (L.) KUNTZE (4)
Picea abies (L.) H.KARST. (4) Sambucus nigra L. (4)
Modulation of immune
system and inflammation
Echinacea purpurea (L.) MOENCH (2) Echinacea purpurea (L.) MOENCH (41)
Salix sp. L. (2) Camellia sinensis (L.) KUNTZE (26)
Thymus vulgaris L. (1) Glycyrrhiza glabra L. (19)
Sambucus nigra L. (1) Origanum vulgare L. (19)
Urtica dioica L. (1) Allium sativum L. (18)
Malva sylvestris L. (1) Salvia officinalis L. (16)
Plantago lanceolata L. (1) Urtica dioica L. (15)
Allium sativum L. (1) Foeniculum vulgare (L.) MILL. (11)
Tilia cordata MILL/Tilia platyphyllos SCOP. (1) Matricaria recutita L. (11)
Artemisia absynthum L. (1) Malva sylvestris L. (9)
Verbascum sp. L. (1) Rumex sp. L. (9)
Armoracia rusticana PH. GÄRTN.(1)
1initial sources = standard literature, based on traditional empiric knowledge and historical literature of veterinary [42–45], and human phytotherapy [46], peer-reviewed
publications of European [47] and Swiss ethnoveterinary medicine [36, 38] and a report of the European Food Safety Authority (EFSA) [48] focusing on the use of plants
as feed additives in animal production; 2Score = 3 x (number of proven effects in clinical studies – number disproof of effects in clinical studies) + 2 x (number of proven
effects in in vivo studies - number of disproof of effects in in vivo studies) + 1 x (number of proven effects in in vitro studies - number of disproof of effects of in vitro
studies) agastrointestinal tract: all plant species recommended for QA 4 times or more in the initial sources, ordered by incidence of recommendation by different
authors as listed in detail in Additional file 2; arespiratory tract: all plant species recommended for QR 4 times or more in the initial sources, ordered by incidence
of recommendation by different authors as listed in detail in Additional file 2; aModulation of immune system and inflammation: includes all plant species
recommended for QL 1 time or more in the initial sources, ordered by incidence of recommendation by different authors as presented in file 2 in greater
detail; bgastrointestinal tract: includes all plant species gathered for QA with a minimum score of 6 ordered by sum of points the plant species gathered;
brespiratory tract: includes all plant species gathered for QR with a minimum score of 4, ordered by sum of points the plant species gathered; bModulation of immune
system and inflammation: includes all plant species gathered for QL with a minimum score of 9, ordered by sum of points the plant species gathered; bold letters =
plant species recommended in initial sources and in peer-reviewed references for same indication
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Relevance for the treatment of livestock diseases
From the 418 references assessed, 46 focused on live-
stock including 19 clinical references for pigs and five
for cattle. Most of these clinical studies used the plants
as a feed additive and not as a pharmaceutical. This
might be due to complex regulatory affairs exacerbating
the licensing and authorization of a medicinal plant or a
plant extract as a veterinary drug.
Due to missing information regarding the absorption of
orally administered medicinal plant compounds by the
gastrointestinal tract, local treatment of gastrointestinal dis-
eases might promising compared to a systemic treatment
of respiratory diseases. Effective concentrations of, e.g. es-
sential oils via inhalation may be obtained in the respiratory
tract, but it is less practicable when larger herds need to be
treated. While pigs as monogastrics might be compared
with humans, calves are young ruminants and the biotrans-
formation of plants secondary metabolites in the foresto-
mach is not well known. However, in suckling calves plant
extracts can be administered by daily milk diet to ensure
bypassing the forestomach by oesophagal groove reflex.
We identified only a few recent references and also
few traditional recommendations for the indication QR
(n = 57) compared to QA (n = 198). Interestingly, similar
findings were reported from ethnoveterinary research
[47, 60]. One explanation might include the challenge of
the treatment of respiratory diseases because systemic
effects are needed to obtain the therapeutic effect com-
pared to primarily local effects. Modulation of the im-
mature or deficient immune system of calves and piglets
provides a starting-point for the prevention of multifac-
torial infectious diseases. In the traditional phytotherapy
literature, effects of medicinal plants on the immune sys-
tem cannot be found frequently. This might be explained
by the fact that immunology is a relatively young scien-
tific field that developed rapidly in recent years. In human
medicine, some immune stimulating preparations are
already available on the market and therefore, a variety of
studies is available. In contrast, for livestock, scientific
knowledge is not transferred to practical use yet.
This review mainly focused on therapeutic options of
medicinal plants. From this point of view, the relevance
of possible toxicity, adverse effects or residues in live-
stock products remains open. Regarding safety aspects
Tussilago farfara L. cannot be recommended as a thera-
peutic medicinal plant due to the presence of toxic pyr-
rolizidine alkaloids. Nevertheless, the majority of plant
species in this review are consumed by humans as food,
spices, luxury foodstuffs or as registered nutraceuticals
and pharmaceuticals. If these plant species are safe for
ingestion in humans, it might be legitimate to transfer
these results to other mammalians with a comparable
metabolism (herbivores and omnivores). Under these
circumstances, risks for humans based on residues in
products from food-producing animals should be neglect-
able. For herbivores and omnivores with a mainly plant-
based ration, safety of the most medicinal plant species
can be supposed. These species may cope with plant sec-
ondary metabolites in a similar way as humans [35].
Promising plant species for gastrointestinal and
respiratory diseases and for modulation of the immune
system and inflammation
Several trials show the equivalence of plant-derived phar-
maceuticals with synthetic ones, but nonetheless there are
some trials showing the contrary. Based on the data pre-
sented in this review, Allium sativum L., Mentha x piper-
ita L. and Salvia officinalis L. carry a high potential for
treatment of gastrointestinal diseases (Table 3). Echinacea
purpurea (L.) MOENCH, Thymus vulgaris L. and Althaea
officinalis L. may be considered for the treatment of
respiratory diseases (Table 4). Regarding the majority
of positive results of studies evaluated, Echinacea pur-
purea (L.) MOENCH, Camellia sinensis (L.) KUNTZE
and Glycyrrhiza glabra L. were found to stimulate the
immune response (Table 5).
Traditionally, plant species with a high content of tan-
ning agents are administered in diarrhea. Allium sativum
L. does not contain tanning agents, but due to its anti-
bacterial, antidiarrheal, anti-inflammatory and immuno-
modulatory effects, it may be used for prophylactic and
acute treatment in diarrhea of calves and piglets. Eight
in vivo and clinical studies were identified for Allium
sativum L. proving these effects, and no studies disprov-
ing them. A trial conducted with neonatal calves showed
that allicin, a main active compound of Allium sativum
L., delayed the onset of diarrhea due to Cryptosporidium
parvum [61]. Two clinical studies demonstrated anti-
diarrheal effects and a reduction of the fecal coliform
count by Allium sativum L.. There is also evidence for
an improvement of performance in pre-ruminant calves
[62, 63]. The immunomodulatory activity of Allium sati-
vum L. in pigs [64, 65] and poultry [66, 67] may hold
true in immunocompromised calves to support their im-
mune defense. Its antibacterial effects on Escherichia coli
and Salmonella ssp. in vitro suggest a high probability of
antibacterial activity in vivo [68–75]. Nevertheless, more
clinical studies are necessary to investigate antiinfective
effects of Allium sativum L. in young farm animals. Al-
lium sativum L. has been reported to exhibit anti-
inflammatory activity in rats [76]. There is also mechan-
istic evidence for anti-inflammatory properties as well as
immunostimulation showed in three in vitro studies,
namely an inhibition of leucocyte migration [77], modu-
lation of interleukin and interferon-gamma expression
[78] and a suppression of nitrogen oxide production in
macrophages [79]. An anti-inflammatory effect may be
useful for the treatment of systemic inflammation
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processes often accompanied with diarrhea. Facing animal
welfare and regarding efficient synthetic non-steroidal and
steroidal anti-inflammatory agents, it is debatable whether
there is a need for plant-derived alternatives. While syn-
thetic non-steroidal and steroidal anti-inflammatory agents
often produce considerable adverse effects including an in-
hibition of mucus production [80, 81], medicinal plants
compass considerable adverse-effects because they contain
several different active compounds which might reduce
the potential of unwanted effects [82]. In in vivo tests for
acute and chronic toxicity, the maximum tolerance dose
and genotoxicity Allium sativum L. was demonstrated to
be relatively safe if administered in therapeutic dosages
[83] and if estimated for the animals metabolic body weight
[84]. With respect to food quality, it must be assured that
residues of Allium sativum L., responsible for the typical
taste of this plant do not result in an altered taste of meat.
To reduce enteral spasm during diarrheal diseases,
Mentha x piperita L. might be an efficient treatment option
based on three clinical studies in humans, demonstrating
efficient spasmolytic activity comparable to butylscopola-
mine [85–87]. The underlying mechanism includes inhib-
ition of smooth muscle contractility through the block of
calcium influx by menthol [88]. In traditional medicine,
Mentha x piperita L. has been used in the therapy of re-
spiratory diseases. Peppermint essential oil showed spas-
molytic activity on rat trachea ex vivo [89]. But there are no
clinical studies in veterinary medicine for Mentha x piper-
ita L. in respiratory disease. No adverse effects have been
reported for Mentha x piperita L. infusions or oral intake
of leaves [90]. Excessive inhalation or local application of
pure Mentha x piperita L. essential oil was shown to lead
to hypersensitivity reactions [56]. Contraindications are se-
vere hepatic damage and cholestasis [43].
Based on this review, the most prominent plant species
for stimulation of the immune system is Echinacea pur-
purea (L.) MOENCH. The main constituents are polysac-
charides, alkylamides, caffeic acid esters and polyacetylenes
[91]. It has been used in therapy for stimulation of the im-
mune system in human medicine, mainly for prevention of
viral infections of the respiratory tract [92]. A total of 23
clinical and in vivo studies revealed multiple effects on the
innate and acquired immune system. Echinacea purpurea
(L.) MOENCH was shown to increase the immune re-
sponse towards swine erysipelas vaccination in piglets [93],
prevented enveloped virus infections in humans [94] and
reduced symptom severity in naturally acquired upper re-
spiratory tract infections in humans [95]. In contrast, seven
clinical or in vivo studies reported the absence of the above
mentioned effects. For example Echinacea purpurea (L.)
MOENCH failed to enhance growth or to show any immu-
nomodulatory effect in one study in pigs [96]. Reasons for
these negative results may be due to a very small number
of individuals, an improper dosage or study design. As
mentioned above, the diversity of non-standardized Echin-
acea preparations with varying chemistry is likely to result
in different findings. In some studies, the dosage was not
reported, and therefore it was not possible to estimate how
much plant material or drug equivalent was administered
per day. Consequently, due to missing data final conclu-
sions cannot be drawn. Nevertheless, eight in vivo studies
reported modulations of immune system and blood cell
count, and no studies were found disproving these effects.
Different Echinacea species were found to increase the total
number of white and red blood cells in mice [97] and
horses [98]. Twenty-six in vitro studies demonstrated the
underlying mechanisms of immunomodulatory effects of
Echinacea purpurea (L.) MOENCH. It was reported to acti-
vate macrophages and natural killer cells [99–101] and to
modulate several cytokines [102–105]. Echinacea purpurea
(L.) MOENCH is known as a safe immunostimulant in
humans and several products are available on the market.
No reported interactions with other drugs and no toxic ef-
fects after overdosage were reported [106]. Possible rare ad-
verse effects such as hypersensitivity reactions are reported,
but no adverse effects have been observed during long-
term administration [107]. In general, Echinacea purpurea
(L.) MOENCH seems to be effective in preventing respira-
tory diseases and as an early intervention immediately after
onset of first symptoms of infectious diseases [95]. How-
ever, further veterinary clinical studies need to be per-
formed, especially to evaluate effective dosages.
In human medicine,Thymus vulgaris L. has been already
effectively used according to its antitussive and mucolytic
effects in the treatment of acute bronchitis, often in com-
binations with other plant species, e. g. Primula veris L.
for its expectorant effects [108–110]. The main active
compound of Thymus vulgaris L. is the essential oil con-
taining thymol, geraniol, thujanol and linalool [111]. The
above mentioned effects still have to be investigated for
veterinary purposes. Nevertheless, an enhancement of the
mucociliary clearance in mice was shown in two in vivo
studies [112, 113]. This effect was explained by an inter-
action with beta2 receptors in rat lung tissue [112]. Add-
itionally, three ex vivo studies demonstrated spasmolytic
effects of Thymus vulgaris L. on tracheal chains compar-
able to theophylline [114–116]. The reported anti-
inflammatory properties [117] and antibacterial effects
found in in vitro studies [118–120] of Thymus vulgaris L.
still needs to be investigated in clinical studies. In vivo
studies on the toxicology of Thymus vulgaris L. leaf extract
showed no toxic potential [121, 122]. In summary, the data
available support the potential for using Thymus vulgaris
L. for treatment of respiratory diseases in livestock.
Camellia sinensis (L.) KUNTZE seems to be useful for
treatment of diarrhea as well as for stimulation of the im-
mune system. Main constituents are polyphenolic com-
pounds (up to 25 % catechin derivatives in non-fermented
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plants, e.g. epigallocatechin), purine alkaloids (caffeine, theo-
bromine, theophylline) and flavonoids [123]. Some clinical
studies reported beneficial effects of Camellia sinensis (L.)
KUNTZE on gut health as indicated by a reduced preva-
lence of postweaning diarrhea in piglets, but also a decrease
in growth performance [124]. An experimental trial on a
diet with Camellia sinensis (L.) KUNTZE whole plant ex-
tract revealed a significant decrease of Clostridia counts, but
also of Enterococci counts in the feces of piglets com-
pared to a standard diet with antibiotics [125]. Two in vivo
studies showed also anti-influenza virus activity in mice
[126] and chicken [127], which might be due to an inhib-
ition of virus adsorption [126]. Fifteen in vitro and five in
vivo studies demonstrated antioxidative [128–130] and anti-
inflammatory [131, 132] effects and a modulation of the im-
mune system [133, 134]. No studies were found disproving
these effects. In mice, the intake of a concentrated extract of
Camellia sinensis (L.) KUNTZE did not lead to unwanted
adverse effects [135]. Despite that Camellia sinensis (L.)
KUNTZE is known to be fairly devoid of unwanted effects,
some reports on liver damage related to the intake of Cam-
ellia sinensis (L.) KUNTZE extract are available [136, 137].
In summary, most reports state that safety of Camellia
sinensis (L.) KUNTZE extract can be supposed, if used ap-
propriately to the recommendations [136]. Therefore, Cam-
ellia sinensis (L.) KUNTZE bears a reliable potential for
prophylaxis and therapy of diseases in calves and piglets.
The main active compound of medicinally used roots of
Glycyrrhiza glabra L. is the saponin glycyrrhizin. Further-
more, it contains flavonoids and isoflavonoids, chalcones,
cumarins and phytosterols [123]. With regard to the inclu-
sion criteria of this review, no clinical studies focusing on
Glycyrrhiza glabra L. could be found. Nevertheless, it was
shown to exhibit immunostimulatory effects in vivo, by
stimulation of cellular and nonspecific response [138]. In
three in vivo and ex vivo models, antitussive [139] and tra-
cheal smooth muscle relaxing activity [140] as well as regu-
lating effects in the gastrointestinal tract were reported
[141]. Four in vitro studies demonstrated its antimicrobial
[142, 143] and antiviral potential by activation of autophagy
[144]. In an assessment of different plant species, Glycyr-
rhiza glabra L. exerted the strongest antiviral activity against
rotavirus [145]. Due to these versatile effects, Glycyrrhiza
glabra L. might be beneficial for prophylaxis and treatment
of virus induced diseases of the respiratory- as well as the
gastrointestinal tract. Regarding the safety of Glycyrrhiza
glabra L., it is important to choose the right dosage due to
the hyper-mineralocorticoid-like effects of glycyrrhizin. An
acceptable daily dosage of 0.015–0.229 mg glycyrrhizin/kg
body weight/day for human and animals was reported [146].
Conclusions
This systematic review identified common medicinal
plant species as a potential future therapeutic option for
gastrointestinal and respiratory diseases in calves and
piglets. Based on their plant specific multi-component
compositions, the versatile effects of medicinal plants as
‘multi-target drugs’ may bear a potential for the treatment
of respiratory and gastrointestinal diseases in calves and
piglets. Medicinal plants are unlikely to replace chemical
medications as a general rule, but they may be a single or
at least a complementary treatment. In concert with hous-
ing, feeding and hygiene, medicinal plants are part of a
sustainable, natural option for improving animal health
and reducing the use of antimicrobials in livestock farm-
ing. The results of this review provide support for a need
for additional in vitro, in vivo and clinical research focused
on phytotherapy for recently emerging and challenging
diseases in livestock. While a large amount of peer-
reviewed studies about medicinal plant species is available,
most of the clinical and experimental studies were per-
formed in humans and experimental animals. More re-
search is needed to evaluate the potential of medicinal
plants for treatment of farm animals. The data from this
review provide guidance on medicinal plants promising
for further investigations in livestock: the most promising
candidates for gastrointestinal diseases are Allium sativum
L., Mentha x piperita L. and Salvia officinalis L.; for dis-
eases of the respiratory tract, Echinacea purpurea (L.)
MOENCH, Thymus vulgaris L. and Althea officinalis L.
were found most promising, and Echinacea purpurea (L.)
MOENCH, Camellia sinensis (L.) KUNTZE, Glycyrrhiza
glabra L. and Origanum vulgare L. were identified as best
candidates for modulation of the immune system and in-
flammation. Based on this review, studies are under way
to investigate the effects of promising medicinal plants in
calves and piglets.
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